Biomedical Engineering and Bioengineering Commons^™

Potent, Rapid And Cost-Effective Influenza Vaccines Made In E. Coli, Thomas Hofstaetter

Vaccine Technology III

The traditional influenza vaccine, trivalent inactivated virus (TIV) has been in use in the United States in one form or another since the 1940s. The system for production involves injecting influenza virus into embryonated hen’s eggs, harvesting the allantoic fluid containing the virus, inactivation with formalin, disruption of the virus with non-ionic detergent, zonal centrifugation to enrich for antigen and a second inactivation step. The recent appearance of the H1N1 swine virus has provided an opportunity to test the pandemic response system established over the past ten years. What we find is that the public health system seems to work …

Iscomatrix™ Adjuvant Links Innate And Adaptive Immune Responses, Debbie Drane

Vaccine Technology III

The ISCOMATRIX™ adjuvant has antigen delivery and presentation properties as well as immunomodulatory capabilities which combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of sub classes of antibodies as well as both CD4+ and CD8+ T cells. A range of ISCOMATRIX™ vaccines (ISCOMATRIX™ adjuvant combined with antigen) have now been tested in clinical trials and have been shown to be generally safe and well tolerated as well as immunogenic, generating both antibody and T cell responses.

The mechanisms by which ISCOMATRIX™ adjuvant facilitates its immune effects is the scope of significant study and …